# Efficacy and Safety Study of bb2121 Versus Standard Regimens in Subjects With Relapsed and Refractory Multiple Myeloma (RRMM)

> **NCT03651128** · PHASE3 · ACTIVE_NOT_RECRUITING · sponsor: **Celgene** · enrollment: 381 (actual)

## Conditions studied

- Multiple Myeloma

## Interventions

- **BIOLOGICAL:** bb2121
- **DRUG:** Daratumumab
- **DRUG:** Pomalidomide
- **DRUG:** Dexamethasone
- **DRUG:** Bortezomib
- **DRUG:** Ixazomib
- **DRUG:** Lenalidomide
- **DRUG:** Carfilzomib
- **DRUG:** Elotuzumab

## Key facts

- **NCT ID:** NCT03651128
- **Lead sponsor:** Celgene
- **Sponsor class:** INDUSTRY
- **Phase:** PHASE3
- **Study type:** INTERVENTIONAL
- **Status:** ACTIVE_NOT_RECRUITING
- **Start date:** 2019-04-16
- **Primary completion:** 2027-04-08
- **Final completion:** 2027-04-08
- **Target enrollment:** 381 (ACTUAL)
- **Last updated:** 2022-12-15


## Primary source

ClinicalTrials.gov registry: https://clinicaltrials.gov/study/NCT03651128

## Citation

> US National Library of Medicine, ClinicalTrials.gov registration NCT03651128, "Efficacy and Safety Study of bb2121 Versus Standard Regimens in Subjects With Relapsed and Refractory Multiple Myeloma (RRMM)". Retrieved via AI Analytics 2026-07-03 from https://api.ai-analytics.org/clinical/NCT03651128. Licensed CC0.

---

*[Clinical trials dataset](/datasets/clinical-trials) · CC0 1.0*